Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1612P - The impact of COVID-19 pandemic on distress level in cancer patients, a cross-sectional multicentric study


16 Sep 2021


ePoster Display


Anuska Budisavljevic


Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713


A. Budisavljevic1, R. Kelemenic-Drazin2, N. Dedic Plavetic3, T. Silovski3, I. Kardum Fucak4

Author affiliations

  • 1 Oncology Department, General Hospital Pula, 52100 - Pula/HR
  • 2 Department For Hematology, Oncology And Clinical Immunology, General Hospital Varazdin, 42000 - Varazdin/HR
  • 3 Department Of Oncology, University Hospital Centre Zagreb, 10000 - Zagreb/HR
  • 4 Department Of Gastroenterology, Hematology And Oncology, General Hospital "Dr. T. Bardek", 48000 - Koprivnica/HR

Abstract 1612P


The pandemic of coronavirus disease 2019 (COVID-19) was declared in March 2020. The first wave of the pandemic was marked by strict epidemiological measures: lockdown, social distancing, and self isolation. Cancer patients receiving systemic oncology treatments were considered a high-risk population regarding COVID19. These new circumstances posed possible obstacles for the treatment continuation, which in turn potentially led to an increase in distress. This study aimed to examine the impact of COVID-19 outbreak on a distress level among cancer patients.


A total of 728 cancer patients, in 9 oncology centers, were approached to participate in the study. The study questionnaire with disease and sociodemographic characteristics was completed by 422 patients. Patients were stratified by cancer type: breast, gastrointestinal (colon, gastric, pancreatic), and other cancer types (lung, prostate, ovarian); and by disease stage, early or metastatic. All patients had to have an ongoing active oncology treatment which required regular visits to outpatient clinics or inpatient oncology departments. Distress level was measured using the Distress Thermometer with a cut-off value of 4.


There were 201 (47%) patients with breast cancer, 130 (32%) patients with gastrointestinal cancer (colon, pancreatic and gastric cancer), and 92 (21%) patients with other types of cancer (lung, prostate, ovarian). A total of 192 (46%) patients had early disease stage while 230 (54%) patients had advanced disease, respectively. A high distress level was reported in 189 (44.8%) of all patients. The breast cancer patients had significantly higher levels of distress when comparing with other types of cancer. There was no significant difference in distress level regarding disease stage.


Almost every second cancer patient with ongoing active oncology treatment was highly distressed during the first wave of the COVID-19 pandemic, regardless of the disease stage. Breast cancer patients tend to have higher levels of distress when comparing with other cancer types. When evaluating distress during a pandemic one should take into account the possible impact of various aspects of COVID-19 disease and pandemic on a distress level in cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings